The protein C pathway: New insights

Thrombosis and Haemostasis

Volumn 78, Issue 1, 1997, Pages 70-74

  Esmon, Charles T ^a,b,c   Ding, Wei ^a   Yasuhiro, Katsuura ^a   Gu, Jian Ming ^b   Ferrell, Gary ^b   Regan, Lisa M ^b   Stearns Kurosawa, Deborah J ^a   Kurosawa, Shimichiro ^a   Mather, Timothy ^a   Laszik, Zolton ^a   Esmon, Naomi L ^a  

^a UNIVERSITY OF OKLAHOMA   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^c OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 5A; CELL RECEPTOR; MEMBRANE RECEPTOR; PROTEIN C; THROMBIN; THROMBOMODULIN;

BLOOD CLOTTING; CONFERENCE PAPER; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RECEPTOR BINDING; THROMBOSIS;

EID: 0030756899     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1657503     Document Type: Conference Paper

References (36)

1. Esmon CT. The roles of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chem 1989;264:4743-6.
2. Dreyfus M, Magny JF, Bridey F, Schwarz HP, Planché C, Dehan M, Tchernia G. Treatment of homozygous protein C deficiency and neonatal purpura fulminans with a purified protein C concentrate. N Engl J Med 1991;325:1565-8.
3. Dahlbäck B. Physiological anticoagulation. Resistance to activated protein C and venous thromboembolism. J Clin Invest 1994;94:923-7.
4. Ohlin A-K, Marlar RA. The first mutation identified in the thrombomodulin gene in a 45-year-old man presenting with thromboembolic disease. Blood 1995;85(2):330-6.
5. Healy AM, Rayburn HB, Rosenberg RD, Weiler H. Absence of the blood-clotting regulator thrombomodulin causes embryonic lethality in mice before development of a functional cardiovascular system. Proc Natl Acad Sci (USA) 1995;92:850-4.
6. Cortellaro M, Boschetti C, Cofrancesco E, Zanussi C, Catalano M, de Gaetano G, Gabrielli L, Lombardi B, Specchia G, Tavazzi L, et al. The PLAT Study: Hemostatic function in relation to atherothrombotic ischemic events in vascular disease patients. Principal results. Arterioscl Thromb 1992;12:1063-70.
7. Gruber A, Griffin JH, Harker LA, Hanson SR. Inhibition of platelet-dependent thrombus formation by human activated protein C in a primate model. Blood 1989;73:639-42.
8. Hanson SR, Griffin JH, Harker LA, Kelly AB, Esmon CT, Gruber A. Antithrombotic effects of thrombin-induced activation of endogenous protein C in primates. J Clin Invest 1993;92:2003-12.
9. De Stefano V, Mastrangelo S, Schwarz HP, Pola P, Flore R, Bizzi B, Leone G. Replacement therapy with a purified protein C concentrate during initiation of oral anticoagulation in severe protein C congenital deficiency. Thromb Haemostas 1993;3:247-9.
10. Powars D, Larsen R, Johnson J, Hulbert T, Sun T, Patch MJ, Francis R, Chan L. Epidemic meningococcemia and purpura fulminans with induced protein C deficiency. Clin Infect Dis 1993;17:254-61.
11. Taylor FB, Jr., Chang A, Hinshaw LB, Esmon CT, Archer LT, Beller BK. A model for thrombin protection against endotoxin. Thromb Res 1984;36:177-85.
12. Taylor FB, Jr., Chang A, Esmon CT, D'Angelo A, Vigano-D'Angelo S, Blick KE. Protein C prevents the coagulopathic and lethal effects of E coli infusion in the baboon. J Clin Invest 1987;79:918-25.
13. Taylor F, Chang A, Ferrell G, Mather T, Catlett R, Blick K, Esmon CT. C4b-binding protein exacerbates the host response to Escherichia coli. Blood 1991;78:357-63.
14. Grey S, Hau H, Salem HH, Hancock WW. Selective effects of protein C on activation of human monocytes by lipopolysaccharide, interferon-gamma, or PMA: Modulation of effects on CD11b and CD14 but not CD25 or CD54 induction. Transplant Proc 1993;25:2913-4.
15. Grey ST, Hancock WW. A physiologic anti-inflammatory pathway based on thrombomodulin expression and generation of activated protein C by human mononuclear phagocytes. J Immunol 1996;156:2256-63.
16. Gerson WT, Dickerman JD, Bovill EG, Golden E. Severe acquired protein C deficiency in purpura fulminans associated with disseminated intravascular coagulation: treatment with protein C concentrate. Pediatrics 1993;91:418-22.
17. Rivard GE, David M, Farrell C, Schwarz HP. Treatment of purpura fulminans in meningococcemia with protein C concentrate. J Pediatr 1995;126(4):646-52.
18. Rivard GE, David M, Farrell C, Gerson W, Dickerman JD, Bovill EG, Schwarz HP. Treatment of purpura fulminans in meningococcemia with protein C concentrate.[Abstract] Thromb Haemost 1993;69:2338
19. Esmon CT, Schwarz HP. An update on clinical and basic aspects of the protein C anticoagulant pathway. Trends Cardiovasc Med 1995;5:141-8.
20. Coughlin SR. Thrombin receptor function and cardiovascular disease. Trends Cardiovasc Med 1994;4:77-83.
21. Fukudome K, Esmon CT. Identification, cloning and regulation of a novel endothelial cell protein C/activated protein C receptor. J Biol Chem 1994;269:26486-91.
22. Bangalore N, Drohan WN, Orthner CL. High affinity binding sites for activated protein C and protein C on cultured human umbilical vein endothelial cells. Independent of protein S and distinct from known ligands. Thromb Haemostas 1994;72(3):465-74.
23. Fukudome K, Kurosawa S, Stearns-Kurosawa DJ, He X, Rezaie AR, Esmon CT. The endothelial cell protein C receptor: Cell surface expression and direct ligand binding by the soluble receptor. J Biol Chem 1996;271:17491-8.
24. Esmon CT. Simionescu N, Simionescu M, editors.Endothelial cell biology. New York: Plenum Publishing, Corp. 1988; 9, Assembly and function of the protein C anticoagulant pathway on endothelium. p. 191-206.
25. Esmon NL. Thrombomodulin. Sem Thromb Hemost 1987;13:454-63.
26. Stearns-Kurosawa DJ, Kurosawa S, Mollica JS, Ferrell GL, Esmon CT. The endothelial cell protein C receptor augments protein C activation by the thrombin-thrombomodulin complex. Proc Natl Acad Sci (USA) 1996;93:10212-6.
27. Mathews II, Padmanabhan KP, Tulinsky A. Structure of a nonadecapeptide of the fifth EGF domain of thrombomodulin complexed with thrombin. Biochemistry 1994;33:13547-52.
28. Stubbs MT, Oschkinat H, Mayr I, Huber R, Angliker H, Stone SR, Bode W. The interaction of thrombin with fibrinogen. A structural basis for its specificity. Eur J Biochem 1992;206:187-95.
29. Rydel TJ, Ravichandran KG, Tulinsky A, Bode W, Huber R, Roitsch C, Fenton JW, II. The structure of a complex of recombinant hirudin and human a-thrombin. Science 1990;249:277-80.
30. Mathews II, Padmanabhan KP, Ganesh V, Tulinsky A, Ishii M, Chen J, Turck CW, Coughlin SR, Fenton JW. Crystallographic structures of thrombin complexed with thrombin receptor peptides: existence of expected and novel binding modes. Biochemistry 1994;33:3266-79.
31. Ye J, Esmon NL, Esmon CT, Johnson AE. The active site of thrombin is altered upon binding to thrombomodulin: Two distinct structural changes are detected by fluorescence, but only one correlates with protein C activation. J Biol Chem 1991;266:23016-21.
32. Mather T, Oganessyan V, Hof P, Huber R, Foundling S, Esmon C, Bode W. The 2.8 Å crystal structure of Gla-domainless activated protein C. EMBO J 1996;15:6822-31.
33. Brinkhous KM, Sigman JL, Read MS, Stewart PF, McCarthy KP, Timony GA, Leppanen SD, Rup BJ, Keith JC, Jr., Garzone PD, et al. Recombinant human factor IX: Replacement therapy, prophylaxis, and pharmacokinetics in canine hemophilia B. Blood 1996;88:2603-10.
34. Cheung W-F, van den Born J, Kuhn K, Kjellen L, Hudson BG, Stafford DW. Identification of the endothelial cell binding site for factor IX. Proc Natl Acad Sci (USA) 1996;93:11068-73.
35. Laszik Z, Esmon CT. The newly identified protein C receptor is present primarily on vascular endothelium of large vessels: Implications for the control of the protein C pathway. [In Press] J Clin Invest 1997.
36. Ding W, Gu J-M, Fukudome K, Laszik Z, Grammas P, Esmon CT. Upregulation of the message for rodent endothelial cell protein C receptor (EPCR) by endotoxin and thrombin. [Abstract] Circulation 1996;94:I694